Muhammad Habibulla Alamin

Muhammad Habibulla Alamin

Auto-generated profile, based on publicly available information

Muhammad Habibulla Alamin

Central South University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2026 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
MD Youshuf Khan RakibMD Youshuf Khan Rakib
MD Youshuf Khan Rakib
MAMuhammad Habibulla Alamin
Muhammad Habibulla Alamin
JLJiamu Li
Jiamu Li
Sheikh Sohan MamunSheikh Sohan Mamun
Sheikh Sohan Mamun
KGKaleb Amsalu Gobena
Kaleb Amsalu Gobena
SRShengbing Ren
Shengbing Ren
Accurate drug–target affinity (DTA) prediction is critical for drug discovery and repurposing. However, existing models often struggle with generalizing to unseen drug–target pairs, lack interpretability, and fail to integrate heterogeneous biological features effectively. To overcome these challenges, we introduce KANPM-DTA, a deep learning framework designed to capture richer biochemical interactions and improve prediction reliability. Specifically, an ESM-guided protein graph construction strategy incorporates evolutionary and structural information to overcome underexplored protein representations. A gated fusion mechanism was employed to integrate drug–protein graph features, while linear attention captures cross-modal dependencies that enhance discriminative power. For the final affinity prediction, a Kolmogorov–Arnold network was used, offering a stronger nonlinear approximation and improved interpretability. Comprehensive experiments on benchmark datasets demonstrate that KANPM-DTA significantly outperforms state-of-the-art methods. On the Davis, KIBA, Metz, and BindingDB datasets, we achieved significant performance improvements under warm setting, with MSE reductions of 6.42%, 4.86%, 4.44%, and 5.46%, CI increases of 0.45%, 0.34%, 0.48%, and 0.80%, and $r_{m}^{2}$ gains of 1.85%, 0.90%, 0.84%, and 1.05%, respectively. Moreover, a case study on the epidermal growth factor receptor further highlights the effectiveness of KANPM-DTA in predicting DTAs for unknown drug–target pairs, emphasizing its potential for real-world applications in drug discovery. However, wet-lab validation is required to assess the applicability of the results.

6 July 2025 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
MRMatiur Rahaman
Matiur Rahaman
BSBandhan Sarker
Bandhan Sarker
MAMuhammad Habibulla Alamin
Muhammad Habibulla Alamin
FFFarzana Ferdousi
Farzana Ferdousi

1 January 2025 in International Journal of Genomics
Verified
Journal Article
Open access
AAAmanat Ullah Arman
Amanat Ullah Arman
MRMd Selim Reza
Md Selim Reza
MAMuhammad Habibulla Alamin
Muhammad Habibulla Alamin
TMTasnia Akter Maya
Tasnia Akter Maya
MHMd. Tofazzal Hossain
Md. Tofazzal Hossain
Prostate cancer (PCa) is a major malignancy affecting men and is a significant contributor to global male mortality. Over the past decade, several new treatments for advanced PCa have been approved; however, opportunities remain for the development of novel therapeutic strategies. Therefore, in this study, we developed an integrated bioinformatics pipeline to identify potential therapeutic targets and repurposed drugs using RNA‐seq datasets, aiming to advance treatment options for PCa. Using the LIMMA approach, 458 common differentially expressed genes (cDEGs) were analyzed from three publicly available microarray datasets, leading to the identification of 15 hub genes (HubGs) through a protein–protein interaction (PPI) network. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses revealed their critical roles in PCa, and lower expressions of five HubGs (BIRC5, CDCA5, CENPF, NUSAP1, and TK1) correlated with better survival. All of these genes could potentially serve as biomarkers for the detection and therapy of PCa. Following that, we considered these possible genes as targets for drugs, performed docking analysis with 255 meta‐drug agents, and identified the top 10 candidate drugs (adapalene, ergotamine, imatinib, dutasteride, vistusertib, risperidone, zafirlukast, irinotecan hydrochloride, drospirenone, and telmisartan). Finally, we evaluated the binding stability of the top‐ranked three complexes—BIRC5–adapalene, BIRC5–imatinib, and TK1–ergotamine—through a 100 nanoseconds (ns) molecular dynamics (MD) simulation conducted using NAMD. The analysis revealed consistent stability across all complexes. This study uniquely combines multidataset transcriptomic integration, HubG prioritization, and MD validation to propose novel biomarker–drug pairings for PCa. The findings offer promising leads for future experimental and clinical validation.

1 September 2026 in IEEE Transactions on Computational Biology and Bioinformatics
Verified
Journal Article
Closed access
QZQichang Zhao
Qichang Zhao
QLQiao Ling
Qiao Ling
MAMuhammad Habibulla Alamin
Muhammad Habibulla Alamin
PSPengcheng Shu
Pengcheng Shu
YHYuqi Hong
Yuqi Hong
JWJianxin Wang
Jianxin Wang